| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T71 |
0-154 |
Sentence |
denotes |
Present results strongly support the need to perform a deeper investigation on the use of raloxifene as a therapeutic agent for the treatment of Covid-19. |
| T72 |
155-365 |
Sentence |
denotes |
As shown in the present communication, its pharmacological profile as a partial BK B2 agonist is expected to antagonize the inflammatory action of BK, shown to be upregulated in Covid-19 patients [12,13,14,15]. |
| T73 |
366-538 |
Sentence |
denotes |
This, in turn, will produce a reduction of cytokine levels, including IL-6, which is the primary proinflammatory cytokine associated with the severity of the illness [5,6]. |
| T74 |
539-684 |
Sentence |
denotes |
On the other hand, its partial agonism profile is expected to maintain a base level of BK, preserving its beneficial cardiovascular effects [42]. |
| T75 |
685-855 |
Sentence |
denotes |
Despite the novel beneficial effects identified, caution should be paid due to the necessary higher dose required for the compound to be used for a novel therapeutic use. |
| T76 |
856-931 |
Sentence |
denotes |
The treatment of osteoporosis requires an oral dose between 30 to 150 mg/d. |
| T77 |
932-1062 |
Sentence |
denotes |
Taking into account its poor bioavailability of 2%, a single dose of 100 mg gives a maximal concentration in plasma of ~2 nM [43]. |
| T78 |
1063-1269 |
Sentence |
denotes |
Concentrations necessary for the therapeutical benefit of raloxifene towards the BK B2 receptor are expected to be, at most, around 100 times higher, which is within the therapeutic window of the drug [44]. |
